专家意见对COVID-19疫苗和克拉德里滨片在MS:一个简单的语言总结。

IF 2.3 Q3 CLINICAL NEUROLOGY Neurodegenerative disease management Pub Date : 2023-02-01 DOI:10.2217/nmt-2022-0027
Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H Hua, Celia Oreja-Guevara, Daniel Selchen, Per Soelberg Sørensen, Patrick Vermersch, Heinz Wiendl, Hashem Salloukh, Bassem Yamout
{"title":"专家意见对COVID-19疫苗和克拉德里滨片在MS:一个简单的语言总结。","authors":"Peter Rieckmann,&nbsp;Diego Centonze,&nbsp;Gavin Giovannoni,&nbsp;Le H Hua,&nbsp;Celia Oreja-Guevara,&nbsp;Daniel Selchen,&nbsp;Per Soelberg Sørensen,&nbsp;Patrick Vermersch,&nbsp;Heinz Wiendl,&nbsp;Hashem Salloukh,&nbsp;Bassem Yamout","doi":"10.2217/nmt-2022-0027","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this summary about?: </strong>People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.</p><p><strong>What were the results?: </strong>The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.</p><p><strong>What do the results mean?: </strong>Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 1","pages":"5-13"},"PeriodicalIF":2.3000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.\",\"authors\":\"Peter Rieckmann,&nbsp;Diego Centonze,&nbsp;Gavin Giovannoni,&nbsp;Le H Hua,&nbsp;Celia Oreja-Guevara,&nbsp;Daniel Selchen,&nbsp;Per Soelberg Sørensen,&nbsp;Patrick Vermersch,&nbsp;Heinz Wiendl,&nbsp;Hashem Salloukh,&nbsp;Bassem Yamout\",\"doi\":\"10.2217/nmt-2022-0027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>What is this summary about?: </strong>People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.</p><p><strong>What were the results?: </strong>The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.</p><p><strong>What do the results mean?: </strong>Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\"13 1\",\"pages\":\"5-13\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2022-0027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2022-0027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

这个总结是关于什么的?患有多发性硬化症(简称MS)的人服用克拉德滨片剂可能会担心他们是否能接种COVID-19疫苗。本摘要详细介绍了先前发表的一篇文章的研究结果,其中一个由10名多发性硬化症专家组成的国际委员会制定了建议,以回答有关服用克拉德滨片剂的多发性硬化症患者(包括复发缓解型或活动性继发性进行性疾病)接种COVID-19疫苗的一些重要问题。结果如何?委员会确定了13项建议,38名投票的MS专家中至少有四分之三(75%)同意这些建议。一般来说,他们建议服用克拉德里滨片剂的MS患者应尽快接种COVID-19疫苗,因为该疫苗被认为既安全又有效,疫苗反应不太可能受到克拉德里滨片剂的影响。这些结果意味着什么?总体而言,服用克拉德滨片剂的多发性硬化症患者应接种COVID-19疫苗以保护自己,除非医疗保健提供者有不同建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.

What is this summary about?: People with multiple sclerosis (shortened to MS) who are taking cladribine tablets may have concerns about whether they can be vaccinated against COVID-19. This summary details the findings from a previously published article, in which an international committee of 10 MS experts developed recommendations to answer some important questions about COVID-19 vaccines in people with MS (including relapsing-remitting or active secondary progressive disease) taking cladribine tablets.

What were the results?: The committee identified 13 recommendations, which were all agreed upon by at least three-quarters (75%) of the 38 voting MS experts. Generally, they recommended that people with MS taking cladribine tablets should be vaccinated for COVID-19 as soon as possible, because the vaccine is thought to be both safe and effective, and vaccine responses were not likely to be affected by cladribine tablets.

What do the results mean?: Overall, people with MS taking cladribine tablets should receive the COVID-19 vaccine to protect themselves, unless advised differently by their healthcare provider.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
35
期刊最新文献
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies. An interdisciplinary approach to rehabilitation in Parkinson's disease: case series. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. Welcome to Volume 14 of Neurodegenerative Disease Management. Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1